Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,870,000 shares, a growth of 32.2% from the February 28th total of 4,440,000 shares. Based on an average trading volume of 2,540,000 shares, the short-interest ratio is currently 2.3 days. Approximately 2.6% of the shares of the company are sold short.

Analysts Set New Price Targets

HOLX has been the topic of a number of recent analyst reports. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Stephens reiterated an “overweight” rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Hold” and an average target price of $84.62.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. General Partner Inc. purchased a new stake in shares of Hologic during the 4th quarter valued at about $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

NASDAQ:HOLX traded up $0.45 during trading hours on Monday, reaching $61.77. 2,036,389 shares of the company traded hands, compared to its average volume of 1,810,593. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm’s 50-day moving average is $65.24 and its 200-day moving average is $73.24. The stock has a market cap of $13.86 billion, a P/E ratio of 19.49, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic has a 1-year low of $60.34 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.